New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major ...

There’s new hope for one of the world’s deadliest cancers. Groundbreaking clinical trial results show that an experimental ...

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

In a 36-patient trial, a vitamin D drug softened the wall around pancreatic tumors, letting chemotherapy and immune cells ...

Investigators evaluated the safety and efficacy of daraxonrasib compared to standard-of-care chemotherapy in patients with ...

Sufficient data for statistical modeling were available for NSCLC trials. The mean sample size of the NSCLC trials was 175 patients. Response rates in the treatment arms for NSCLC ranged from 7% to 42 ...

Akeso’s Phase 3 ASCO data show ivonescimab improved overall survival vs PD-1 chemo in squamous NSCLC—key read for investors.

Childhood cancer survival rates have now reached 80 to 85 per cent, with early diagnosis and advanced treatments dramatically ...

An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic ...